Americans who fill prescriptions through Canadian mail-order pharmacies have 10 days before a federal customs change could slow, complicate, or stop their deliveries. A U.S. Customs and Border Protection rule on international mail reaches a key compliance date on Oct. 22, and patient advocates warn that imported medicines could get caught in it.
The rule does not mention prescription drugs by name. It covers nearly everything arriving through the international postal network, from clothing to toys. But according to the Associated Press, medications mailed from abroad will need additional data and a customs bond once the change takes hold, and the practical result could be delays, refusals or added costs.
The stakes are highest for older adults and people with chronic conditions who rely on lower Canadian prices to stay on their medicines. About 2.3 million U.S. adults reported buying prescription drugs abroad to save money, according to a study in JAMA Network Open published in 2020 and cited by the AP.
The Rule Never Names Medicines, but the Fine Print Matters
CBP published the interim final rule in June. It indefinitely suspends the de minimis exemption that once let mail shipments worth $800 or less enter duty-free, and it creates a new informal entry process for mail shipments valued at $2,500 or less.
Under that process, only an owner, purchaser, or licensed customs broker can file the entry, and the filer must hold a customs bond. Each package must be reported with details that include a 10-digit tariff classification, country of origin, value, and tracking number.
The Oct. 22 date matters because of a grace period written into the rule. Until then, CBP has let goods subject to other federal agencies’ import requirements use the simpler postal process. After Oct. 22, those goods must go through formal entry, a more demanding customs filing. Prescription drugs are regulated by the FDA, which is why medicines appear likely to fall into that group even though the text never names them.
CBP said it would open a voluntary electronic option, called the Entry Type 13 test, as an alternative to formal entry for these shipments when the grace period ends. Whether Canadian pharmacies will use it, and how quickly, has not been made public.
In the rule, the agency said it wanted to prevent “the flooding of low-value merchandise into the United States,” including illicit drugs such as fentanyl. Congress has separately written an end to the de minimis exemption into law, effective July 1, 2027.
Florida and Border-State Patients Weigh the Price Gap
The price difference can be large. A study by the Campaign for Personal Prescription Importation found in an August study that a three-month supply of the blood thinner Eliquis cost $565 from a Canadian mail-order pharmacy, compared with roughly $1,017 through Amazon’s pharmacy or $1,029 through GoodRx, the AP reported.
Ken Hunter, the group’s executive director, said price-cutting efforts have not reached everyone. “There has been a lot of talk of lowering drug prices, but in many cases it doesn’t cover all drugs for all people for all conditions,” he told the AP.
Geography shapes the burden. People who live near the Canadian border can sometimes fill prescriptions in person, but many Floridians cannot easily travel to Canada. Three Florida Republican members of Congress, Aaron Bean, Gus Bilirakis and Scott Franklin, wrote to the administration urging CBP and the FDA to make sure constituents seeking lower prices are not swept up by the rule. Florida’s own federally authorized Canadian importation program has stalled.
Separately, 71 House Democrats led by Reps. Mark Pocan and Jan Schakowsky asked HHS, the Department of Homeland Security, the FDA and CBP to delay the new procedures for prescription medicines. A White House spokesperson told the AP the administration remains committed to lowering drug costs and pointed to its pricing agreements with drugmakers.
Enforcement Questions Remain Open Ten Days Out
Much is still uncertain. The administration could drop the rule, change it or decide not to enforce it, the AP noted, and CBP did not respond to the AP’s requests for comment. Until officials say how mailed prescriptions will be handled, patients are planning around a moving target.
The legal backdrop matters too. Importing prescription drugs for personal use has generally been illegal for individuals, as the American Medical Association has noted, even though federal enforcement has historically been limited. The new rule changes customs paperwork, not the underlying FDA law.
Patients who travel to Canada in person face a different situation. The rule states that it does not affect the separate customs exemption for personal articles carried by travelers, although FDA rules on bringing medicines across the border still apply.
Steps to Take Before the Next Refill Ships
People who depend on a Canadian pharmacy should contact it now and ask how it plans to ship after Oct. 22, whether it will use a customs broker, and whether any new fees will be passed along. Ordering a refill early may help bridge a delay, but patients should confirm the pharmacy can still deliver.
It is also worth asking a U.S. doctor or pharmacist about backup options. Generic alternatives, manufacturer assistance programs, discount cards and Medicare drug-price negotiation may lower costs for some medicines. No one should stop or ration a prescribed drug without talking to a clinician, since gaps in blood thinners, inhalers or heart medicines can be dangerous.
Caution is warranted with websites that suddenly promise easy workarounds. Pharmacist associations in both countries have long warned that some sites posing as Canadian pharmacies sell counterfeit or unsafe products.
KFF Health News flagged the rule in its Oct. 9 briefing as a growing affordability concern. The next real test comes after Oct. 22, when patients begin to see whether their packages arrive on time.
Key Questions Answered
What changes on Oct. 22?
A grace period in a CBP mail rule ends, and goods subject to other federal agencies’ import requirements must use formal customs entry. Prescription drugs, which the FDA regulates, appear likely to be affected.
Does the rule ban Canadian prescriptions?
No. The rule does not name medicines, but added filing, bonding and data requirements could cause delays, refusals or extra costs for mailed prescriptions.
How many Americans could be affected?
About 2.3 million U.S. adults reported buying prescription drugs abroad to save money, according to a 2020 JAMA Network Open study. Not all of them use mail delivery from Canada.
Who faces the greatest burden?
Older adults and people with chronic conditions who rely on lower foreign prices are most exposed. Patients far from the border, including many in Florida, have fewer alternatives.
Could the rule still change?
Yes. The AP reported that the administration could drop, alter, or decline to enforce the rule, and lawmakers from both parties have asked for assurances on personal-use prescriptions.
What should patients do now?
Contact the pharmacy about shipping plans, ask a U.S. clinician or pharmacist about backup options, and avoid unverified websites. Do not stop a prescribed medicine without medical advice.
Published by Medicaldaily.com
